Introduction: This study reports the incidence, anatomic location, and outcomes of graft-vs-host disease (GVHD) at a single active intestine transplant center.
| INTRODUC TI ON
Intestine transplant is a potentially life-saving procedure for patients who have experienced intestine failure, unresectable mesenteric tumors, portomesenteric thrombosis, among other intraabdominal pathologies. Although advances have occurred, intestine transplant continuous to be replete with risk of morbidity and mortality.
Serious post-transplant complications commonly arise limiting the efficacy of the intestine graft as well as the long-term survival of many transplant recipients.
Graft-vs-host disease (GVHD) is a serious and potentially lifethreatening complication arising in intestine, other solid organ, and allogenic hematopoietic stem cell (HSC) transplantation. GVHD occurs when T cells from the donor tissue are activated by host antigen-presenting cells causing donor lymphocytes to initiate an immune response against recipient tissue. All host tissues are susceptible to attack by activated donor cells, but the skin, liver, and gastrointestinal tract are the most common sites of disease. 1 The incidence of GVHD in HSC transplantation is high and has been shown to be 50% in some studies. 2 In solid organ transplantation, the incidence of GVHD is much lower, but varies greatly by type of organ transplanted. Small intestine transplants, whether as a multivisceral graft or as an isolated
| ME THODS
Medical records for all patients receiving an intestine transplant at Graft-vs-host disease was diagnosed based on clinical indications and histopathologic evidence using biopsies from affected areas (skin, bone marrow, lungs). All patients with an unexplained skin rash in the post-transplant period underwent skin biopsy to determine whether the rash represented GVHD. In all cases, the dermatopathologists were able to conclusively determine whether the rash represented GVHD, vs some other etiology. Diagnosis of GVHD in the lung and bone marrow also required tissue biopsy. Open biopsy of the lung in an already compromised patient is a challenging clinical decision, and we only pursued lung biopsy in those patients with a compromised pulmonary status for whom all other etiologies had been excluded. Bone marrow biopsy was more easily obtained, but generally just demonstrated a marrow devoid of a cellular components. No liver biopsies were taken to assess for GVHD in patients with a liver exclusive graft; therefore, no GVHD of the liver is noted.
Additionally, a single case of GVHD in the central nervous system was diagnosed via a computed tomography (CT) scan. The CT scan showed demyelination of the brainstem, periventricular white matter, and cerebellar hemispheres bilaterally, which is consistent with GVHD in the CNS. Pharmacy records were reviewed in documented cases to assess therapeutic interventions and to confirm therapy administration for the diagnosis of GVHD. At this center, treatment of GVHD consisted of a steroid taper only, and no other therapy was employed. Cutaneous GVHD was graded (I-IV) according to consensus criteria.
8
Intestine and multivisceral transplant procedures performed at our center have been previously described. [9] [10] [11] Intestine decontamination was never administered to the donor or to the recipient as part of intestine transplant process. 12 When another center was procuring the donor pancreas, the duodenum was stapled prior to use of intestine decontamination to prevent exposure of the isolated intestine graft to the decontamination solution. 13 
| RE SULTS
Altogether, 236 intestine transplants were performed on 214 patients, with 21 patients undergoing multiple intestine transplant procedures. The median age of transplant recipients was 42 years, with 184 adult patients (>18 years) and 52 pediatric patients (≤18 years).
Intestine failure was the primary indication for transplantation in the majority of cases (63%). Portomesenteric thrombosis and nonresectable tumors were the other conditions most commonly necessitating intestine transplant. The majority of patients (62%) received a MVT, while 26% received an IT and 12% a MMVT. No pediatric patient received a MMVT. Donors had a median age of 18 years, and trauma was the primary cause of death ( Table 1 ).
The rate of GVHD in this cohort of patients was 16%. The incidence of GVHD in MVT was significantly higher (20%) than that seen in MMVT (14%) and IT (7%; P = 0.05). In adult patients, a similar pattern was observed with 22% of MVT, 14% of MMVT, and only 4% of IT patients developing GVHD (P = 0.02). In the pediatric population, the overall incidence was slightly lower (13%) with only a slight difference in the rate between MVT and IT recipients (15% vs 11%; Table 2 ). Overall, the median time post-transplant to the development of GVHD in affected patients was 83 days (62 days in pediatrics and 90 days in adults), with 57% of patients diagnosed in the first 90 days post-transplant and 89% within the first year. All affected patients were treated with a long steroid taper until the skin lesions disappeared. With a short course of therapy, the skin lesions often returned. However, in all cases, the lesions did eventually disappear, though a taper of many month duration was required.
A total of six different pediatric patients developed seven cases of GVHD, with one patient developing GVHD after each of their two transplants. Most of the pediatric patients were male (72%), and the majority received a MVT graft (72%). All of the affected pediatric patients had cutaneous manifestations of GVHD, and only one child developed extracutaneous disease, which was found in the lung. All but one pediatric patient (86%) developed disease in the first 90 days post-transplant. Only one (17%) child died from the direct effects of GVHD, and two (33%) died within the first year post-diagnosis (Table 3) . It is unclear whether other deaths, most commonly resulting from infection and sepsis, were related to GVHD or its treatment (a prolonged course of moderate-dose steroids).
Graft-vs-host disease occurred in 29 different adult patients, with one patient having the disease twice after two separate trans- Table 3) .
This study finds an increasing graft volume being associated with a higher risk of GVHD. Therefore, an analysis was performed to analyze the ratio of donor to recipient height, weight, and BMI.
When comparing these ratios in GVHD and non-GVHD groups, the ratios ranged from 0.99 to 1.01, and there was no significant difference between the groups. These data provide evidence that donor-to-recipient size ratio is not predictive of a diagnosis of GVHD (Table 4) . Alternatively, all liver inclusive grafts also had higher graft volume. 
| D ISCUSS I ON
This study reports the incidence, location, and outcomes of GVHD in a large patient population undergoing intestine transplantation at a single center. The incidence among this cohort was 16%, which is congruent with previously published data that show GVHD to range from 6% to 29%. 3, 15 The median time to GVHD diagnosis was Similar to previously published data, the incidence of GVHD in this patient population increased as the size of the graft increased (IT to MMVT to MVT). [15] [16] [17] This increase has been speculated to be from an increase in the amount of lymphoid tissue transplanted, but a definitive mechanism has yet to be elucidated. 17 In response to this observation, the present study tested the hypothesis that the ratio of donor to recipient size would be >1.00 in patients who develop GVHD. In theory, as donor size increased in relation to recipient size the volume of immunologically active cells transplanted would be proportionally larger, perhaps leading to an increase in the incidence of GVHD. This hypothesis was not supported by the data as the ratios of height, weight, and BMI in all the groups tested varied little from 1.00. Thus, the ratio of donor to recipient height, weight, and BMI does not appear to be an important risk factor for the prediction of GVHD development. A more promising finding was that liver inclusion was associated with higher risk of GVHD (P = 0.02). The liver is known to be very immunologically active and may mediate this process in these patients. However, GVHD in liver transplant only patients is quite rare, providing evidence against this idea. Further work is needed to identify reliable predictors for the development of GVHD. Also, additional research is required to elucidate the underlying cause of the increase in GVHD incidence among MVT recipients when compared to IT recipients, especially if the liver is involved.
Other variables not analyzed in this paper that may influence the development of GVHD include splenectomy and the use of rATG.
Splenectomy has been associated with the development of GVHD on incidence of GVHD in this cohort, but this is impossible to determine without a comparison group as all patients in this cohort did receive rATG.
As previously noted from existing publications, GVHD in solid organ transplantation is associated with high post-transplant mortality. 5 A similar trend is observed in intestine transplantation, with 77% of patients dying within the follow-up period, with a median time to death of 12.6 months post-diagnosis of GVHD. 16 High mortality was also observed in the patient population from the present study, with 54% of patients dying during the first year after diagnosis Currently, there is no consensus on the best therapy to reverse GVHD, and treatment options are lacking in effectiveness.
Described treatment options consist of increasing immunosuppression, whether through a steroid taper, anti-lymphocytic drugs, anti-interleukin-2 antibodies, or other biologic therapies. 21, 22 Cellbased treatments are now being studied, but none have gained widespread use. Mesenchymal stem cell therapy has been described as GVHD prophylaxis and was effective in a small patient cohort. 23 Extracorporeal photophoresis has also been reported as therapy for GVHD, but this was reported to be ineffective. 3 Novel therapies targeting Jak-1/Jak-2 such as ruxolitinib have shown promise in treating acute and steroid-resistant GVHD, potentially offering another treatment option for patients who suffer from this complication. 24 In conclusion, graft-vs-host disease is a serious and potentially life-threatening complication occurring after HSC and solid organ transplantation. Currently, there are few effective treatment options, and further work is required to develop to effect therapies.
Results from this study suggest that GVHD in the intestine transplant population is more likely to be seen in patients receiving a liver graft, those with a worse HLA match, and patients who have not experienced any rejection. Donor-recipient size discordance does not appear to predict GVHD in this population. GVHD is associated with high mortality in a patient population known to have poor long-term survival. 
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